<p>Arrowhead Pharmaceuticals, Inc.（纳斯达克股票代码：ARWR - 获取免费报告）内部人员 Tracie Oliver 在 7 月 2 日星期二的交易中出售了 9,394 股公司股票。这些股票的平均价格为 25.28 美元，总交易额为 237,480.32 美元。交易结束后，该内部人员现在直接持有公司股票 127,107 股，价值约 3,213,264.96 美元。该销售交易已在提交给证券交易委员会的法律文件中披露，可以通过 SEC 网站查看。</p>
<h2>Arrowhead Pharmaceuticals 股价表现</h2>
<ul>
<li>想在生物技术领域获得多元化上涨？看看 LABU</li>
</ul>
<p>纳斯达克股票代码 ARWR 周三在午盘交易中下跌 0.15 美元，至 25.07 美元。该股交易量为 360,710 股，相比平均交易量 1,325,371 股。Arrowhead Pharmaceuticals, Inc.一年内最低股价为 20.67 美元，最高股价为 39.83 美元。该股市值为 31.1 亿美元，市盈率为-5.90，贝塔系数为 0.94。该公司的 50 天简单移动平均价格为 24.49 美元，200 天简单移动平均价格为 28.33 美元。</p>
<p>Arrowhead Pharmaceuticals（纳斯达克股票代码 ARWR - 获取免费报告）最近公布了截至 5 月 9 日星期四的季度财报。这家生物技术公司报告该季度每股亏损 1.02 美元，低于市场预期的每股亏损 0.06 美元。Arrowhead Pharmaceuticals 的净资产收益率为-140.72%，净利润率为-163.32%。去年同期，该公司每股收益为 0.45 美元。该季度公司的营收同比下降了 100.0%。股票研究分析师平均预计，Arrowhead Pharmaceuticals, Inc.本财年每股盈利将达到-3.05 美元。</p>
<h2>对 Arrowhead Pharmaceuticals 的对冲基金看法</h2>
<p>最近，对冲基金调整了他们对该股票的持股。O Shaughnessy Asset Management LLC 在第三季度新建了一份 Arrowhead Pharmaceuticals 的持仓，价值 25.7 万美元。Qube Research &amp; Technologies Ltd 在第三季度将其 Arrowhead Pharmaceuticals 的持仓增加了 98.2%。Qube Research &amp; Technologies Ltd 现在拥有 71,558 股该生物技术公司股票，价值 192.3 万美元，较之前增加了 35,463 股。Glenmede Trust Co. NA 在第三季度将其 Arrowhead Pharmaceuticals 的持股增加了 68.6%。Glenmede Trust Co. NA 现在拥有 16,905 股该生物技术公司股票，价值 45.4 万美元，较之前增加了 6,876 股。Seven Eight Capital LP 在第三季度将其 Arrowhead Pharmaceuticals 的持股增加了 92.6%。Seven Eight Capital LP 现在拥有 24,474 股该生物技术公司股票，价值 65.8 万美元，较之前增加了 11,764 股。最后，Sectoral Asset Management Inc.在第三季度将其 Arrowhead Pharmaceuticals 的持股增加了 9.5%。Sectoral Asset Management Inc.现在拥有 157,552 股该生物技术公司股票，价值 423.3 万美元，较之前增加了 13,630 股。该股票的 62.61% 由机构投资者和对冲基金持有。</p>
<h2>分析师设定新的股价目标</h2>
<p>一些研究分析师对该股票发表了评论。摩根大通将 Arrowhead Pharmaceuticals 的目标股价从 36.00 美元降至 27.00 美元，并在 5 月 13 日星期一的研究报告中为该公司设定了 “持平” 评级。Chardan Capital 重申了对 Arrowhead Pharmaceuticals 的 “买入” 评级，并在 6 月 26 日星期三的研究报告中设定了 60.00 美元的目标股价。HC Wainwright 重申了对 Arrowhead Pharmaceuticals 的 “买入” 评级，并在 6 月 11 日星期二的研究报告中设定了 90.00 美元的目标股价。StockNews.com 在一份研究报告中将 Arrowhead Pharmaceuticals 的评级提升至 “卖出”。最后，Cantor Fitzgerald 在 6 月 20 日星期四的研究报告中重申了对 Arrowhead Pharmaceuticals 的 “超重” 评级。一位分析师对该股票进行了卖出评级，三位分析师给予持有评级，七位分析师给予买入评级。根据 MarketBeat 的数据，该股目前的平均评级为 “中等买入”，并且有一个 47.89 美元的共识目标股价。</p>
<p><strong>获取我们对 Arrowhead Pharmaceuticals 的最新研究报告</strong></p>
<h2>Arrowhead Pharmaceuticals 公司简介（获取免费报告）</h2>
<p>Arrowhead Pharmaceuticals, Inc.致力于开发治疗美国难治性疾病的药物。该公司的产品管线包括 Plozasiran，目前处于 2b 期和一项 3 期临床试验阶段，用于治疗高甘油三酯血症、混合性脂质代谢异常和乳糜微粒血症综合征；Zodasiran 目前处于 2b 临床试验阶段，用于治疗脂质代谢异常和高甘油三酯血症；ARO-PNPLA3 目前处于 1 期临床试验阶段，用于治疗非酒精性脂肪肝患者；ARO-RAGE 目前处于 1/2a 期临床试验阶段，用于治疗炎症性肺部疾病；ARO-MUC5AC 目前处于 1/2a 期临床试验阶段，用于治疗黏液阻塞性肺部疾病。</p>
<h2>精选故事</h2>
<ul>
<li>五只我们比 Arrowhead Pharmaceuticals 更喜欢的股票</li>
<li>为何特别股息对收入投资者来说是一个令人愉快的惊喜</li>
<li>AbbVie 股票：投资者购买的完美机会</li>
<li>哪些华尔街分析师最准确？</li>
<li>忘记 NVIDIA：超微电脑股票在动量方面领先</li>
<li>如何计算股票利润</li>
<li>GitLab 股票反弹：其复苏内幕报道</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVJXUg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVJXUg"/></p>
<p><em>此即时新闻警报是由 Narrative Science 技术和 MarketBeat 的财务数据生成，旨在为读者提供最快速和最准确的报道。本故事在发布前经过 MarketBeat 编辑团队审核。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com。</em></p>
<p>→ 操作替换拜登已启动（来自自由港协会）(广告)</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04NTg5?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04NTg5"/></p>
<h2>现在是否值得投资箭头制药公司（Arrowhead Pharmaceuticals）1,000 美元？</h2>
<p>在考虑投资箭头制药公司之前，您可能想要听听这个。</p>
<p>MarketBeat 追踪华尔街评级最高、表现最佳的研究分析师以及他们每天向客户推荐的股票。MarketBeat 已经确定了五只顶级分析师悄悄告诉客户现在应该购买的股票... 而箭头制药公司并不在名单上。</p>
<p>尽管箭头制药公司目前在分析师中拥有 “中等买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

箭头制药

<p>箭头制药公司内部人士 Tracie Oliver 出售了 9,394 股股票，总交易额为 $237,480.32。该公司股价一直在波动，分析师已经为该股设定了一个价格目标。这属于与商业相关的信息</p>

<p>Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Get Free Report) insider Tracie Oliver sold 9,394 shares of the business's stock in a transaction on Tuesday, July 2nd. The shares were sold at an average price of $25.28, for a total transaction of $237,480.32. Following the transaction, the insider now directly owns 127,107 shares of the company's stock, valued at approximately $3,213,264.96. The sale was disclosed in a legal filing with the Securities &amp; Exchange Commission, which is accessible through the SEC website.</p>
<div class="lb-trans"><p>Arrowhead Pharmaceuticals, Inc.（纳斯达克股票代码：ARWR - 获取免费报告）内部人员 Tracie Oliver 在 7 月 2 日星期二的交易中出售了 9,394 股公司股票。这些股票的平均价格为 25.28 美元，总交易额为 237,480.32 美元。交易结束后，该内部人员现在直接持有公司股票 127,107 股，价值约 3,213,264.96 美元。该销售交易已在提交给证券交易委员会的法律文件中披露，可以通过 SEC 网站查看。</p>
</div><h2>Arrowhead Pharmaceuticals Price Performance</h2>
<ul>
<li>Want Diversified Upside in Biotechnology? Check out LABU</li>
</ul>
<div class="lb-trans"><h2>Arrowhead Pharmaceuticals 股价表现</h2>
<ul>
<li>想在生物技术领域获得多元化上涨？看看 LABU</li>
</ul>
</div><p>NASDAQ:ARWR traded down $0.15 during midday trading on Wednesday, reaching $25.07. The stock had a trading volume of 360,710 shares, compared to its average volume of 1,325,371. Arrowhead Pharmaceuticals, Inc. has a 1-year low of $20.67 and a 1-year high of $39.83. The stock has a market capitalization of $3.11 billion, a P/E ratio of -5.90 and a beta of 0.94. The firm's fifty day simple moving average is $24.49 and its 200-day simple moving average is $28.33.</p>
<div class="lb-trans"><p>纳斯达克股票代码 ARWR 周三在午盘交易中下跌 0.15 美元，至 25.07 美元。该股交易量为 360,710 股，相比平均交易量 1,325,371 股。Arrowhead Pharmaceuticals, Inc.一年内最低股价为 20.67 美元，最高股价为 39.83 美元。该股市值为 31.1 亿美元，市盈率为-5.90，贝塔系数为 0.94。该公司的 50 天简单移动平均价格为 24.49 美元，200 天简单移动平均价格为 28.33 美元。</p>
</div><p>Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) last announced its quarterly earnings data on Thursday, May 9th. The biotechnology company reported ($1.02) earnings per share for the quarter, missing the consensus estimate of ($0.06) by ($0.96). Arrowhead Pharmaceuticals had a negative return on equity of 140.72% and a negative net margin of 163.32%. During the same period last year, the business posted $0.45 EPS. The company's revenue for the quarter was down 100.0% on a year-over-year basis. On average, equities research analysts anticipate that Arrowhead Pharmaceuticals, Inc. will post -3.05 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>Arrowhead Pharmaceuticals（纳斯达克股票代码 ARWR - 获取免费报告）最近公布了截至 5 月 9 日星期四的季度财报。这家生物技术公司报告该季度每股亏损 1.02 美元，低于市场预期的每股亏损 0.06 美元。Arrowhead Pharmaceuticals 的净资产收益率为-140.72%，净利润率为-163.32%。去年同期，该公司每股收益为 0.45 美元。该季度公司的营收同比下降了 100.0%。股票研究分析师平均预计，Arrowhead Pharmaceuticals, Inc.本财年每股盈利将达到-3.05 美元。</p>
</div><h2>Hedge Funds Weigh In On Arrowhead Pharmaceuticals</h2>
<div class="lb-trans"><h2>对 Arrowhead Pharmaceuticals 的对冲基金看法</h2>
</div><p>Hedge funds have recently modified their holdings of the stock. O Shaughnessy Asset Management LLC bought a new position in Arrowhead Pharmaceuticals in the 3rd quarter valued at $257,000. Qube Research &amp; Technologies Ltd grew its position in shares of Arrowhead Pharmaceuticals by 98.2% during the 3rd quarter. Qube Research &amp; Technologies Ltd now owns 71,558 shares of the biotechnology company's stock worth $1,923,000 after buying an additional 35,463 shares during the period. Glenmede Trust Co. NA raised its stake in shares of Arrowhead Pharmaceuticals by 68.6% during the third quarter. Glenmede Trust Co. NA now owns 16,905 shares of the biotechnology company's stock worth $454,000 after buying an additional 6,876 shares during the last quarter. Seven Eight Capital LP lifted its holdings in Arrowhead Pharmaceuticals by 92.6% in the third quarter. Seven Eight Capital LP now owns 24,474 shares of the biotechnology company's stock valued at $658,000 after buying an additional 11,764 shares during the period. Finally, Sectoral Asset Management Inc. boosted its stake in Arrowhead Pharmaceuticals by 9.5% in the third quarter. Sectoral Asset Management Inc. now owns 157,552 shares of the biotechnology company's stock valued at $4,233,000 after acquiring an additional 13,630 shares during the last quarter. 62.61% of the stock is owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>最近，对冲基金调整了他们对该股票的持股。O Shaughnessy Asset Management LLC 在第三季度新建了一份 Arrowhead Pharmaceuticals 的持仓，价值 25.7 万美元。Qube Research &amp; Technologies Ltd 在第三季度将其 Arrowhead Pharmaceuticals 的持仓增加了 98.2%。Qube Research &amp; Technologies Ltd 现在拥有 71,558 股该生物技术公司股票，价值 192.3 万美元，较之前增加了 35,463 股。Glenmede Trust Co. NA 在第三季度将其 Arrowhead Pharmaceuticals 的持股增加了 68.6%。Glenmede Trust Co. NA 现在拥有 16,905 股该生物技术公司股票，价值 45.4 万美元，较之前增加了 6,876 股。Seven Eight Capital LP 在第三季度将其 Arrowhead Pharmaceuticals 的持股增加了 92.6%。Seven Eight Capital LP 现在拥有 24,474 股该生物技术公司股票，价值 65.8 万美元，较之前增加了 11,764 股。最后，Sectoral Asset Management Inc.在第三季度将其 Arrowhead Pharmaceuticals 的持股增加了 9.5%。Sectoral Asset Management Inc.现在拥有 157,552 股该生物技术公司股票，价值 423.3 万美元，较之前增加了 13,630 股。该股票的 62.61% 由机构投资者和对冲基金持有。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析师设定新的股价目标</h2>
</div><p>Several research analysts have commented on the stock. Morgan Stanley decreased their target price on shares of Arrowhead Pharmaceuticals from $36.00 to $27.00 and set an &#34;equal weight&#34; rating for the company in a research report on Monday, May 13th. Chardan Capital reaffirmed a &#34;buy&#34; rating and set a $60.00 target price on shares of Arrowhead Pharmaceuticals in a research note on Wednesday, June 26th. HC Wainwright reissued a &#34;buy&#34; rating and set a $90.00 price objective on shares of Arrowhead Pharmaceuticals in a research note on Tuesday, June 11th. StockNews.com raised shares of Arrowhead Pharmaceuticals to a &#34;sell&#34; rating in a research report on Tuesday. Finally, Cantor Fitzgerald reaffirmed an &#34;overweight&#34; rating on shares of Arrowhead Pharmaceuticals in a research note on Thursday, June 20th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and seven have assigned a buy rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of &#34;Moderate Buy&#34; and a consensus price target of $47.89.</p>
<div class="lb-trans"><p>一些研究分析师对该股票发表了评论。摩根大通将 Arrowhead Pharmaceuticals 的目标股价从 36.00 美元降至 27.00 美元，并在 5 月 13 日星期一的研究报告中为该公司设定了 “持平” 评级。Chardan Capital 重申了对 Arrowhead Pharmaceuticals 的 “买入” 评级，并在 6 月 26 日星期三的研究报告中设定了 60.00 美元的目标股价。HC Wainwright 重申了对 Arrowhead Pharmaceuticals 的 “买入” 评级，并在 6 月 11 日星期二的研究报告中设定了 90.00 美元的目标股价。StockNews.com 在一份研究报告中将 Arrowhead Pharmaceuticals 的评级提升至 “卖出”。最后，Cantor Fitzgerald 在 6 月 20 日星期四的研究报告中重申了对 Arrowhead Pharmaceuticals 的 “超重” 评级。一位分析师对该股票进行了卖出评级，三位分析师给予持有评级，七位分析师给予买入评级。根据 MarketBeat 的数据，该股目前的平均评级为 “中等买入”，并且有一个 47.89 美元的共识目标股价。</p>
</div><p><strong>Get Our Latest Research Report on Arrowhead Pharmaceuticals</strong></p>
<div class="lb-trans"><p><strong>获取我们对 Arrowhead Pharmaceuticals 的最新研究报告</strong></p>
</div><h2>Arrowhead Pharmaceuticals Company Profile (Get Free Report)</h2>
<div class="lb-trans"><h2>Arrowhead Pharmaceuticals 公司简介（获取免费报告）</h2>
</div><p>Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.</p>
<div class="lb-trans"><p>Arrowhead Pharmaceuticals, Inc.致力于开发治疗美国难治性疾病的药物。该公司的产品管线包括 Plozasiran，目前处于 2b 期和一项 3 期临床试验阶段，用于治疗高甘油三酯血症、混合性脂质代谢异常和乳糜微粒血症综合征；Zodasiran 目前处于 2b 临床试验阶段，用于治疗脂质代谢异常和高甘油三酯血症；ARO-PNPLA3 目前处于 1 期临床试验阶段，用于治疗非酒精性脂肪肝患者；ARO-RAGE 目前处于 1/2a 期临床试验阶段，用于治疗炎症性肺部疾病；ARO-MUC5AC 目前处于 1/2a 期临床试验阶段，用于治疗黏液阻塞性肺部疾病。</p>
</div><h2>Featured Stories</h2>
<ul>
<li>Five stocks we like better than Arrowhead Pharmaceuticals</li>
<li>Why Special Dividends Can be a Delightful Surprise for Income Investors</li>
<li>AbbVie Stock: A Perfect Dip for Investors to Buy</li>
<li>Which Wall Street Analysts are the Most Accurate?</li>
<li>Forget NVIDIA: Super Micro Computer Stock Leads in Momentum</li>
<li>How to Calculate Stock Profit</li>
<li>GitLab Stock Rebounds: The Inside Story of Its Comeback</li>
</ul>
<div class="lb-trans"><h2>精选故事</h2>
<ul>
<li>五只我们比 Arrowhead Pharmaceuticals 更喜欢的股票</li>
<li>为何特别股息对收入投资者来说是一个令人愉快的惊喜</li>
<li>AbbVie 股票：投资者购买的完美机会</li>
<li>哪些华尔街分析师最准确？</li>
<li>忘记 NVIDIA：超微电脑股票在动量方面领先</li>
<li>如何计算股票利润</li>
<li>GitLab 股票反弹：其复苏内幕报道</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVJXUg" alt="" original-src="https://www.marketbeat.com/scripts/InsiderTradesChart.ashx?Prefix=NASDAQ&amp;Symbol=ARWR"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻警报是由 Narrative Science 技术和 MarketBeat 的财务数据生成，旨在为读者提供最快速和最准确的报道。本故事在发布前经过 MarketBeat 编辑团队审核。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><p>→ Operation Replace Biden is a Go (From The Freeport Society)(Ad)</p>
<div class="lb-trans"><p>→ 操作替换拜登已启动（来自自由港协会）(广告)</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04NTg5" alt="" original-src="https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx?TriggeredCampaignID=8589&amp;Placement=NativeDisplay&amp;Source=NativeDisplay"/></p>
<h2>Should you invest $1,000 in Arrowhead Pharmaceuticals right now?</h2>
<div class="lb-trans"><h2>现在是否值得投资箭头制药公司（Arrowhead Pharmaceuticals）1,000 美元？</h2>
</div><p>Before you consider Arrowhead Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑投资箭头制药公司之前，您可能想要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Arrowhead Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 追踪华尔街评级最高、表现最佳的研究分析师以及他们每天向客户推荐的股票。MarketBeat 已经确定了五只顶级分析师悄悄告诉客户现在应该购买的股票... 而箭头制药公司并不在名单上。</p>
</div><p>While Arrowhead Pharmaceuticals currently has a &#34;Moderate Buy&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>尽管箭头制药公司目前在分析师中拥有 “中等买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

箭头制药公司（纳斯达克：ARWR）的内部人士 Tracie Oliver 出售了 9,394 股股票